SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : UK AND EUROPEAN BIOTECHS.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (6)12/16/1996 1:52:00 PM
From: James Reynolds   of 64
 
James,

In answer to your questions regarding Chiroscience:

1. The best way to obtain information on the Company is to fax your
details to Andy Burrows, Chiroscience's Corporate Communications Manager, who is based in Cambridge, England. He will forward to you an information pack. His fax number is:

001-144-1223-428720

2. The market cap of Chirocience pre the Darwin merger is around $400 million. Following the Darwin acquisition, which is being funded by the issue of new shares, the market cap will rise to around $500 million.

3. The Company has the following drugs in clinical trials:

Levobupivacaine; this is a single isomer version of bupivacaine, a
long acting local anaesthetic. It is in Phase III trials with an expected launch date of late 1998. Analysts are forecasting peak sales in excess of œ150 million.

D3967; this a single isomer version of an existing breast cancer drug. In Phase III with results expected mid 1997.

D7991; this drug is a combination of the cytotoxic drug, Ifosfamide, with the neuroprotectant methylene blue. In Phase II.

D5410; this is the first of the Company's novel drugs and is an MMP inhibitor for treating arthritis. In Phase I trials.

D2785; this is a single isomer version of the deficit disorder drug Methylphenidate and is being developed in partnership with Medeva. In Phase I.

D4418; this is a PDE IV inhibitor for treatment of asthma which will enter clinical trials in early 1997.

Verapamil isomer;this cardiovascular drug is being developed in collaboration with Knoll (BASF)and will enter Phase I trials in early 1997.

MMP inhibitor for cancer; this drug should enter Phase I in 1997.

I hope this is helpful,

Regards,

James
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News